Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor

References

• Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, Idzan SR, . Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol. 2006;72:588–96.
   PubMed Web of Science ®Google Scholar
• De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov. 2003;2:581–7.
   PubMed Web of Science ®Google Scholar
• Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, . Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102:2728–30.
   PubMed Web of Science ®Google Scholar
• Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K, . Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:1095–102.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, . Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720–6.
   PubMed Web of Science ®Google Scholar
• Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, . Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant. 2010;45:39–47.
   PubMed Web of Science ®Google Scholar
• Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, . The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005;106:1867–74.
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Veldwijk MR, Seeger T, Schubert M, Laufs S, Topaly J, . A combination of granulocyte–colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy. 2009;11:992–1001.
   PubMed Web of Science ®Google Scholar
• Mohty M. Stem-cell collection before high-dose therapy for multiple myeloma: time has come to raise the standards! Leukemia. 2009;23:1689–90.
   Google Scholar
• Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, . Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009;15: 249–56.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Rzhetsky A, Hsu LC, Chang C. Human aldehyde dehydrogenase gene family. Eur J Biochem. 1998;251: 549–57.
   PubMedGoogle Scholar
• Duester G. Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and retinoic acid. Eur J Biochem. [Review] 2000;267:4315–24.
   PubMedGoogle Scholar
• Christ O, Lucke K, Imren S, Leung K, Hamilton M, Eaves A, . Improved purification of hematopoietic stem cells based on their elevated aldehyde dehydrogenase activity. Haematologica. 2007;92:1165–72.
   PubMedGoogle Scholar
• Hess DA, Wirthlin L, Craft TP, Herrbrich PE, Hohm SA, Lahey R, . Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood. 2006;107:2162–9.
   PubMed Web of Science ®Google Scholar
• Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, Ludeman SM, . Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA. 1999;96:9118–23.
   PubMed Web of Science ®Google Scholar
• Cheung AM, Wan TS, Leung JC, Chan LY, Huang H, Kwong YL, . Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia. 2007;21:1423–30.
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, Lister TA, . Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells. 2005;23:752–60.
   PubMed Web of Science ®Google Scholar
• Lioznov MV, Freiberger P, Kroger N, Zander AR, Fehse B. Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants. Bone Marrow Transplant. 2005;35:909–14.
   PubMed Web of Science ®Google Scholar
• Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54.
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Haas R, Conradt C, Murea S, Witt B, Mohle R, . Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood. 1995;85:2619–26.
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Schmitt K, Veldwijk MR, Topaly J, Benner A, Zeller WJ, . Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol. 1999;105: 786–94.
   PubMed Web of Science ®Google Scholar
• Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, . Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547–55.
   PubMed Web of Science ®Google Scholar
• Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, . Poor mobilization of hematopoietic stem cells: definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant. 2010;16:490–9.
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, . Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 2004; 37:1253–62.
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Ehninger G, Hubel K, Topaly J, Goldschmidt H, Ho AD, . Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant. 2009;45:269–75.
   Web of Science ®Google Scholar
• Gentry T, Foster S, Winstead L, Deibert E, Fiordalisi M, Balber A. Simultaneous isolation of human BM hematopoietic, endothelial and mesenchymal progenitor cells by flow sorting based on aldehyde dehydrogenase activity: implications for cell therapy. Cytotherapy. 2007;9:259–74.
   Web of Science ®Google Scholar
• Ran D, Schubert M, Pietsch L, Taubert I, Wuchter P, Eckstein V, . Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol. 2009; 37:1423–34.
   PubMed Web of Science ®Google Scholar
• Hess DA, Meyerrose TE, Wirthlin L, Craft TP, Herrbrich PE, Creer MH, . Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood. 2004;104: 1648–55.
   PubMed Web of Science ®Google Scholar
• Povsic TJ, Zavodni KL, Kelly FL, Zhu S, Goldschmidt-Clermont PJ, Dong C, . Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity. J Am Coll Cardiol. 2007;50:2243–8.
   PubMed Web of Science ®Google Scholar
• Zhang WB, Navenot JM, Haribabu B, Tamamura H, Hiramatu K, Omagari A, . A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem. 2002;277:24515–21.
   PubMed Web of Science ®Google Scholar
• Oelschlaegel U, Bornhauser M, Boxberger S, Kroschinsky F, Illmer T, Hoelig K, . Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma. Ann Hematol. 2007;86:569–73.
   PubMedGoogle Scholar
• Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, . G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3:687–94.
   PubMed Web of Science ®Google Scholar